



FIBROKNOWLEDGE

GLOBAL REFERENCE LIST

EMERGING SCIENCE OF FIBROMYALGIA: ADDITIONAL READING

FEATURED ARTICLES

Gracely RH, Petzke F, Wolf JM, Clauw DJ.

Functional Magnetic Resonance Imaging Evidence of Augmented Pain Processing in Fibromyalgia.
Arthritis Rheum. 2002;46(5):1333-1343.

Sinclair D, Starz TW, Turk DC.

The manual tender point survey.

National Fibromyalgia Association Web site.

<http://www.fmaware.org/site/News2?page=NewsArticle&id=6263>.

Accessed August 17, 2009.

Vaerø H, Helle R, Forre O, Kåas E, Terenius L.

Elevated CSF levels of substance P and high incidence of Raynaud phenomenon in patients with fibromyalgia: new features for diagnosis.

Pain. 1988;32:21-26.

Wolfe F, Smythe HA, Yunus MB et al.

The American College of Rheumatology 1990 criteria for the classification of fibromyalgia. Report of the Multicenter Criteria Committee.

Arthritis Rheum. 1990;33:160-172.

ADDITIONAL ARTICLES

Arnold LM, Hudson JI, Hess EV, et al.

Family study of fibromyalgia.

Arthritis Rheum. 2004;50(3):944-952.

Arnold LM, Lu Y, Crofford LJ, et al.

A Double-Blind, Multicenter Trial Comparing Duloxetine With Placebo in the Treatment of Fibromyalgia Patients With or Without Major Depressive Disorder.

Arthritis Rheum. 2004;50(9):2974-2984.

Bradley LA, Alberts KR, Alarcon GS, et al.

Abnormal brain regional cerebral blood flow (rCBF) and cerebrospinal fluid (CSF) levels of substance P (SP) in patients and non-patients with fibromyalgia (FM).

Arthritis Rheum. 1996;suppl 9:212. Abstract 1109.

Burckhardt CS, Goldenberg D, Crofford L, et al.

Guideline for the Management of Fibromyalgia Syndrome Pain in Adults and Children. APS Clinical Practice Guidelines Series, No. 4.

Glenview, Ill: American Pain Society; 2005.

Burke A, Smyth EM, FitzGerald GA.

Analgesic-antipyretic agents.

In: Brunton LL, Lazo JS, Parker KL, eds. *Goodman & Gilman's The Pharmacological Basis of Therapeutics.* 11th ed. New York, NY: McGraw-Hill; 2006: 681.

Chakrabarty S, Zoorob R. Fibromyalgia.

Am Fam Physician.

2007;76(2): 247-254.

Classification of Diseases, 9th Revision codes.

J Clin Rheumatol. 2006;12(3):124-128.

ADDITIONAL ARTICLES (continued)

Giordano J and Schatman ME.

Pain Physician. 2008;11:483-490.

Goldenberg DL, Burckhardt C, Crofford L.

Management of fibromyalgia syndrome.

JAMA. 2004;292:2388-2395.

Gottschalk A, Smith DS.

New concepts in acute pain therapy: preemptive analgesia.

Am Fam Physician. 2001;63:1979-1984.

Gracely RH, Petzke F, Wolf JM, Clauw DJ.

Functional Magnetic Resonance Imaging Evidence of Augmented Pain Processing in Fibromyalgia.

Arthritis Rheum. 2002;46(5):1333-1343.

Harding SM.

Sleep in fibromyalgia patients: subjective and objective findings.

Am J Med Sci. 1998;315:367-376.

Henriksson KG.

Fibromyalgia – from syndrome to disease. Overview of pathogenetic mechanisms.

J Rehabil Med. 2003;(suppl 41):89-94.

Jones J, Rutledge DN, Jones KD, Matallana L, Rooks DS.

Self-assessed physical function levels of women with fibromyalgia: a national survey.

Women's Health Issues. 2008;18:406-412.

Kuchinad A, Schweinhardt P, Seminowicz DA, Wood PB, Chizh BA, Bushnell MC.

Accelerated brain gray matter loss in fibromyalgia patients: premature aging of the brain?

J Neurosci. 2007;27(15):4004-4007.

Leavitt F, Katz RS, Golden HE, Glickman PB, Layfer LF.

Comparison of pain properties in fibromyalgia patients and rheumatoid arthritis patients.

Arthritis Rheum. 1986;29:775-781.

Luerding R, Weigand T, Bogdahn U, Schmidt-Wilcke T.

Working memory performance is correlated with local brain morphology in the medial frontal and anterior cingulate cortex in fibromyalgia patients: structural correlates of pain-cognition interaction.

Brain. 2008;131:3222-3231.

Lutz J, Jäger L, de Quervain D, et al.

White and gray matter abnormalities in the brain of patients with fibromyalgia: a diffusion-tensor and volumetric imaging study.

Arthritis Rheum. 2008;58(12):3960-3969.

Mease P.

Fibromyalgia syndrome: review of clinical presentation, pathogenesis, outcome measures, and treatment.

J Rheumatol. 2005;32(suppl 75):6-21.

National Pain Foundation Web Site: Available at:

<http://nationalpainfoundation.org/articles/849/facts-and-statistics>.

Accessed July 21, 2009.

ADDITIONAL ARTICLES (continued)

Roizenblatt S, Moldofsky H, Benedito-Silva AA, Tufik S.

Alpha sleep characteristics in fibromyalgia.

Arthritis Rheum. 2001;44:222-230.

Russell IJ, Orr MD, Littman B, Vipraio GA, Alboukrek D, Michalek JE, Lopez Y, MacKillip F.

Elevated cerebrospinal fluid levels of substance P in patients with the fibromyalgia syndrome.

Arthritis Rheum. 1994;37:1593-1601.

Russell IJ, Orr MD, Michalek JE.

Substance P [SP], SP endopeptidase activity [SPE] and SP N-terminal peptide [SP1-7] in fibromyalgia syndrome [FS] cerebrospinal fluid [CSF].

Myopain 1995: Abstracts from the 3rd World Congress on Myofascial Pain and Fibromyalgia; July 30-August 3, 1995; San Antonio, TX.

Sarchielli P, Mancini ML, Floridi A, et al.

Increased levels of neurotrophins are not specific for chronic migraine: evidence from primary fibromyalgia syndrome.

J Pain. 2007;8:737-745.

Schmidt-Wilcke T, Luerding R, Weigand T, et al.

Striatal grey matter increase in patients suffering from fibromyalgia- a voxel-based morphometry study.

Pain. 2007;132(suppl 1):S109-S116.

Sinclair D, Starz TW, Turk DC.

The manual tender point survey.

National Fibromyalgia Association Web site.

<http://www.fmaware.org/site/News2?page=NewsArticle&id=6263>.

Accessed August 17, 2009.

Silverman SL, Martin SA.

Assessment tools and outcome measures used in the investigation of fibromyalgia.

In: Wallace DJ, Clauw DJ, eds. *Fibromyalgia & Other Central Pain Syndromes*. Philadelphia, PA: Lippincott, Williams & Wilkins; 2005:309-319.

Staud R, Rodriguez ME.

Mechanisms of disease: pain in fibromyalgia syndrome.

Nat Clin Pract Rheumatol. 2006;2:90-98.

Staud R.

Biology and therapy of fibromyalgia: pain in fibromyalgia syndrome.

Arthritis Res Ther. 2006;8(3):208-214.

Weir PT, Harlan GA, Nkoy FL, Jones SS, Hegmann KT, Gren LH, Lyon JL.

The incidence of fibromyalgia and its associated comorbidities.

J Clin Rheumatol. 2006;12:124-128.

White KP, Nielson WR, Harth M, Ostbye T, Speechley M.

Does the label "fibromyalgia" alter health status, function, and health service utilization? A prospective, within-group comparison in a community cohort of adults with chronic widespread pain.

Arthritis Rheum. 2002;47:260-265.

ADDITIONAL ARTICLES (continued)

Williams DA, Clauw DJ.

Understanding Fibromyalgia: Lessons from the Broader Pain Research Community.

J Pain. 2009;10(8):777-791.

Wolfe F and Rasker JJ.

Fibromyalgia.

In: *Firestein, ed. Kelly's Textbook of Rheumatology, 8th Edition.* St. Louis, MO: WB Saunders Co; 2008.

Wolfe F, Ross K, Anderson J, Russell IJ, Hebert L.

The prevalence and characteristics of fibromyalgia in the general population.

Arthritis Rheum. 1995;38:19-28.

Wolfe F, Smythe HA, Yunus MB et al.

The American College of Rheumatology 1990 criteria for the classification of fibromyalgia. Report of the Multicenter Criteria Committee.

Arthritis Rheum. 1990;33:160-172.

Woolf CJ.

Pain: Moving from Symptom Control toward Mechanism-Specific Pharmacologic Management.

Ann Intern Med. 2004;140:441-451.